Biotechnology companies deploying artificial intelligence systems face significant risks of model failure without establishing three foundational elements, according to new industry guidance. The analysis emphasizes that AI models in biotech applications require sound data quality, appropriate model selection, and robust governance frameworks to prevent deployment failures.
The warning comes as biotech firms increasingly integrate AI into drug discovery, clinical trial design, and regulatory submissions. According to the analysis, AI models that appear reliable during development phases may fail catastrophically when deployed in real-world biotechnology environments without proper oversight structures.